JP2023535695A - コロナウイルス感染症の治療及び予防のための方法及び組成物 - Google Patents

コロナウイルス感染症の治療及び予防のための方法及び組成物 Download PDF

Info

Publication number
JP2023535695A
JP2023535695A JP2023504023A JP2023504023A JP2023535695A JP 2023535695 A JP2023535695 A JP 2023535695A JP 2023504023 A JP2023504023 A JP 2023504023A JP 2023504023 A JP2023504023 A JP 2023504023A JP 2023535695 A JP2023535695 A JP 2023535695A
Authority
JP
Japan
Prior art keywords
ace2
cov
coronavirus
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535695A5 (https=
JPWO2022020353A5 (https=
Inventor
ジェイムズ トールチア，
ゴードン ジェイ． フリーマン，
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2023535695A publication Critical patent/JP2023535695A/ja
Publication of JP2023535695A5 publication Critical patent/JP2023535695A5/ja
Publication of JPWO2022020353A5 publication Critical patent/JPWO2022020353A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023504023A 2020-07-20 2021-07-20 コロナウイルス感染症の治療及び予防のための方法及び組成物 Pending JP2023535695A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053817P 2020-07-20 2020-07-20
US63/053,817 2020-07-20
US202163150686P 2021-02-18 2021-02-18
US63/150,686 2021-02-18
PCT/US2021/042372 WO2022020353A2 (en) 2020-07-20 2021-07-20 Methods and compositions for treatment and prevention of coronavirus infection

Publications (3)

Publication Number Publication Date
JP2023535695A true JP2023535695A (ja) 2023-08-21
JP2023535695A5 JP2023535695A5 (https=) 2024-07-30
JPWO2022020353A5 JPWO2022020353A5 (https=) 2024-07-30

Family

ID=77301019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504023A Pending JP2023535695A (ja) 2020-07-20 2021-07-20 コロナウイルス感染症の治療及び予防のための方法及び組成物

Country Status (8)

Country Link
US (1) US20230272359A1 (https=)
EP (1) EP4182458A2 (https=)
JP (1) JP2023535695A (https=)
KR (1) KR20230058045A (https=)
CN (1) CN116171324A (https=)
AU (1) AU2021312238A1 (https=)
CA (1) CA3189732A1 (https=)
WO (1) WO2022020353A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CA3185230A1 (en) * 2020-07-06 2022-01-13 Shengjiang Liu Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
US20230374153A1 (en) * 2022-04-13 2023-11-23 Paradigm Immunoterapeutics, Inc. METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-CoV-2
CN119265271B (zh) * 2024-12-09 2025-04-22 上海益诺思生物技术股份有限公司 一种评价ade效应的系统及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070032A1 (en) * 1999-05-13 2000-11-23 Zymogenetics, Inc. Zace2: a human metalloenzyme
JP2002525108A (ja) * 1998-09-30 2002-08-13 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド アンジオテンシン変換酵素相同物およびその使用
US20070238681A1 (en) * 2005-03-08 2007-10-11 Dobie Kenneth W Modulation of ace2 expression
JP2008540600A (ja) * 2005-05-19 2008-11-20 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 肺損傷を治療するためのレニンアンギオテンシン系の阻害剤の使用
JP2014514287A (ja) * 2011-03-29 2014-06-19 ロシュ グリクアート アーゲー 抗体Ｆｃ変種
WO2014160499A2 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
JP2018035138A (ja) * 2014-12-23 2018-03-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
TW201402611A (zh) * 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
WO2021183404A1 (en) * 2020-03-07 2021-09-16 Planet Biotechnology, Inc. Ace2-fc fusion proteins for sars-cov-2 mitigation
CN113444710A (zh) * 2020-03-25 2021-09-28 上海英脉德医疗科技有限公司 ACE2-Fc融合蛋白及其用途
WO2021202427A2 (en) * 2020-03-29 2021-10-07 R-Pharm Overseas, Inc. Ace2-derived composition and use thereof
JP2023526540A (ja) * 2020-05-22 2023-06-21 フォーマイコン アーゲー Ａｃｅ２融合タンパク質及びその使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525108A (ja) * 1998-09-30 2002-08-13 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド アンジオテンシン変換酵素相同物およびその使用
WO2000070032A1 (en) * 1999-05-13 2000-11-23 Zymogenetics, Inc. Zace2: a human metalloenzyme
US20070238681A1 (en) * 2005-03-08 2007-10-11 Dobie Kenneth W Modulation of ace2 expression
JP2008540600A (ja) * 2005-05-19 2008-11-20 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 肺損傷を治療するためのレニンアンギオテンシン系の阻害剤の使用
JP2014514287A (ja) * 2011-03-29 2014-06-19 ロシュ グリクアート アーゲー 抗体Ｆｃ変種
WO2014160499A2 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
JP2018035138A (ja) * 2014-12-23 2018-03-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRUSE ROBERT K.: "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan,", F1000RESEARCH, vol. 9:72, JPN6023036936, 18 February 2020 (2020-02-18), ISSN: 0005828658 *

Also Published As

Publication number Publication date
US20230272359A1 (en) 2023-08-31
WO2022020353A3 (en) 2022-03-10
WO2022020353A2 (en) 2022-01-27
EP4182458A2 (en) 2023-05-24
CA3189732A1 (en) 2022-01-27
AU2021312238A1 (en) 2023-02-23
KR20230058045A (ko) 2023-05-02
CN116171324A (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
JP2023535695A (ja) コロナウイルス感染症の治療及び予防のための方法及び組成物
CN115244077B (zh) 蛋白质治疗剂
Jing et al. ACE2‐based decoy receptors for SARS coronavirus 2
CN114478758B (zh) 靶向SARS-CoV-2的纳米抗体及制备方法和应用
WO2021205184A1 (en) Polypeptide
Naidoo et al. The potential of nanobodies for COVID-19 diagnostics and therapeutics
EP2968453A2 (en) Stabilized single human cd4 domains and fusion proteins
JP2025170319A (ja) Ｓａｒｓ－ｃｏｖ－２阻害剤
Wines et al. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
EP4402180A1 (en) Multivalent polypeptide constructs capable of binding viral spike proteins and methods of using the same
TW202144406A (zh) ＳＡＲＳ－ＣｏＶ－２抗體及其應用
CA3257654A1 (en) METHODS OF PREVENTION OR TREATMENT OF RESPIRATORY VIRUS INFECTION, PARTICULARLY SARS-CoV-2
US20230310584A1 (en) Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
TW202228765A (zh) 重組ACE2-Fc融合分子以及製造與使用其的方法
Nishioka et al. Engineered DPP4 decoy confers broad-spectrum inhibition of MERS-CoV infection
JP2023537546A (ja) 組換えａｃｅ２－ｆｃ融合分子、その製造方法及びその使用
Schepens et al. Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents
Song et al. Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein
Case et al. Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice
EP4335870A1 (en) Peptide therapeutics against sars-cov-2 spike protein
JPH10509865A (ja) 細菌膜上で発現される呼吸器多核体ウイルスプロテインｇ
RU2777073C1 (ru) Однодоменное антитело для нейтрализации вирусов и его модификации, и способ их применения для экстренной профилактики заболеваний, вызываемых вирусом гриппа А
Gach et al. Phagocytic Clearance of SARS-CoV-2 Nucleocapsid-and RNA-Containing Immune Complexes Drives Inflammatory Cytokine Production and Endothelial Dysfunction
WO2024197134A1 (en) Coronavirus spike protein-based vaccines
CN117659181A (zh) 针对sars-cov-2刺突蛋白的肽治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251022

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20251202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331